Novo Nordisk, the Danish pharmaceutical giant renowned for its diabetes and weight-loss medications, including the blockbuster drugs Ozempic and Wegovy, announced impressive third-quarter earnings despite challenges with production constraints. Novo Nordisk profits
As Europe’s most valuable company and a key driver of the Danish economy, Novo Nordisk revised its 2024 sales forecast, now expecting a 23% to 27% increase from the previous year, up from the earlier estimate of 22% to 28%. The company cited strong expected volume growth alongside ongoing capacity limitations at some of its manufacturing sites.
Robust growth amid market demand
In a statement released to shareholders, Novo Nordisk reported a 21% rise in net profit, amounting to DKK 204.7 billion for the July-to-September period. Additionally, sales surged 22% to reach USD 60 billion, although this figure fell slightly short of analysts’ expectations.
To address the increasing demand for its new generation of weight-loss treatments using semaglutides, Novo Nordisk is ramping up its manufacturing capabilities. In particular, sales of Wegovy, which has received approval to treat obesity in multiple countries, including Britain, Denmark, France, Germany, Norway, and the United States, rose by an impressive 42% in the first nine months of this year. The drug also secured approval for use in China in June.
Furthermore, the company’s other popular semaglutide product, Ozempic—an injectable treatment for diabetes that has gained popularity for its weight loss benefits—saw sales soar by 54% during the same timeframe.
Obesity remains a pressing global health crisis, currently affecting 900 million people worldwide. It impacts over 40% of Americans and nearly a quarter of Europeans, posing significant health risks such as diabetes, certain cancers, and complications from diseases like Covid-19. The difficulty of treating obesity contributes to its high costs for healthcare systems, as its causes can be multifaceted, often involving both lifestyle and genetic factors.
With a commanding 74% market share in weight-loss treatments, Novo Nordisk is well-positioned to address the growing demand for effective solutions in this important health sector.
Novo Nordisk profits
Source: Novo Nordisk
